Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$4.73 USD
-0.04 (-0.84%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.82 +0.09 (1.90%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXEO 4.73 -0.04(-0.84%)
Will LXEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LXEO
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Meta, Microsoft upgraded: Wall Street's top analyst calls
Oppenheimer Initiates Coverage on Lexeo Therapeutics (LXEO) with Outperform Rating | LXEO Stock News
Lexeo Therapeutics (LXEO) Receives Positive Start by Oppenheimer
Lexeo Therapeutics initiated with bullish view at Oppenheimer, here's why